Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT02 in relapsed or refractory hematologic malignancies
NCT07107204Phase 2Not yet recruiting
- Sponsor
- BioTroy Therapeutics
- Start
- Oct 2025
- Primary completion
- Jan 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of BT02 in leukemia, lymphoma, multiple myeloma (MM), sponsored by BioTroy Therapeutics. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
BT02
03
Conditions
leukemialymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT07107204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07107204.